Variant Thrombin Proteins Modulate Hemostasis Without Cofactors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current coagulation cascade proteins often require cofactors for efficient substrate cleavage, and there is a need for proteins with enhanced or reduced coagulation function to modulate hemostasis in patients.
Innovation Solution
Development of variant thrombin zymogen/protease proteins with altered amino acid sequences, such as Ile-Val-Glu, to modulate the coagulation cascade by influencing regulatory sites, allowing for the creation of pharmaceutical compositions with anticoagulant or procoagulant properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current coagulation cascade proteins are used, then they can perform coagulation function, but they require cofactors for efficient substrate cleavage which increases system complexity
Solution Approach 1:
The patent extracts and modifies the N-terminal sequence of thrombin to create variant forms that inherently possess enhanced coagulation activity without requiring external cofactors. By taking out the specific N-terminal sequence (Ile-Val-Glu) and engineering variants thereof, the invention eliminates the dependency on cofactor proteins, thereby reducing system complexity while maintaining or enhancing coagulation function.
2Adaptability or versatility
If variant thrombin proteins with altered amino acid sequences are developed, then hemostasis modulation capability is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent applies local quality by making specific, targeted modifications to the N-terminal sequence of thrombin (positions 321-323) rather than redesigning the entire protein. By altering only the critical N-terminal residues to create variants like Ile-Val-Glu, the invention achieves enhanced hemostasis modulation capability while minimizing manufacturing complexity, as the core protein structure and production processes remain unchanged.
3Productivity
If cofactor proteins are used to increase cleavage rate, then substrate cleavage efficiency is improved, but the system requires additional components which reduces ease of operation
Solution Approach 1:
The patent implements self-service by engineering variant thrombin proteins that possess intrinsic high catalytic activity without requiring external cofactor proteins. The modified N-terminal sequence enables the thrombin variant to autonomously achieve rapid substrate cleavage, eliminating the need for additional cofactor components and thereby simplifying the system's ease of operation while maintaining high productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The variant thrombin proteins effectively modulate hemostasis by altering the rate and specificity of cleavage reactions, providing therapeutic options for disorders like thrombosis, thrombocytopenia, and stroke, and can be administered as pharmaceutical compositions or expressed using nucleic acid vectors.
Implementation Method 1
The zymogens possess ∼10,000-fold or less proteolytic activity when compared to the serine proteases produced following activation. Initiation of coagulation at the site of vascular damage leads to a series of reactions in which a zymogen is converted to a protease through specific proteolytic cleavage
Implementation Method 2
This culminates in blood cell activation and the conversion of soluble fibrinogen to insoluble fibrin and hence the formation of the clot
Data Source
AI summary
Novel thrombin/prothrombin protease/zymogen variants which have anticoagulation activity and methods of use thereof are disclosed.